Sort
10,766 grants matching “checkpoint inhibitor”
Role of physical exercise-induced microbiota changes in immunotherapy resistant preclinical melanoma
$48,974Catherine Phelps · University Of Pittsburgh At Pittsburgh · F31 · FY2025 · CA
Targeting TEAD in melanoma drug-tolerant persister cells
$48,974Connor Ott · Thomas Jefferson University · F31 · FY2024 · CA
Understanding the role of altered lipid metabolism in CD8 T cell exhaustion within the tumor microenvironment
$48,974Kellie Spahr · University Of Pittsburgh At Pittsburgh · F31 · FY2024 · CA
Dissecting the tumor cell-immune TME axis to identify therapeutically actionable vulnerabilities that potentiate immunotherapy in GBM
$48,974Amanda Johnson · Johns Hopkins University · F99 · FY2024 · CA
Interrogating the role of mutant KRAS allelic imbalance and co-mutated genes in targeted therapy response of NSCLC
$48,974Bianca Diaz · Weill Medical Coll Of Cornell Univ · F31 · FY2024 · CA
DUSP2 in Negative Regulation of Cytotoxic T Cell Responses to Immunotherapy
$48,974Emilia R Dellacecca · Mayo Clinic Rochester · F31 · FY2024 · CA
BUBR1 in the Spindle Checkpoint and Tumor Suppression
$48,950Institute For Cancer Prevention · R01 · FY2001 · CA
Characterization of the BRCT-mediated ATRIP recruitment
$48,796Andrew R Snyder · Wistar Institute · F32 · FY2006 · CA
Interrogating the role of BLTP3A in organizing protective immunity in ovarian cancer
$48,759Elaheh Hosseini · Rutgers Biomedical And Health Sciences · F99 · FY2025 · CA
Immunology
$48,718Claudio Anasetti · H. Lee Moffitt Cancer Ctr & Res Inst · P30 · FY2018 · CA
Immunology
$48,717Claudio Anasetti · H. Lee Moffitt Cancer Ctr & Res Inst · P30 · FY2017 · CA
PIK3C2A is a vulnerable immunotherapeutic target in triple-negative breast cancer combination therapy
$48,632Xiyu Wang · Indiana University Indianapolis · F30 · FY2025 · CA
The Role of 53BP1 Interacting Proteins in Regulation of DNA Repair Choice
$48,576Jinesh Shailesh Gheeya · Rbhs -Cancer Institute Of New Jersey · F30 · FY2016 · CA
Therapeutic and Sustained Cytokine Delivery at the Tumor Site Using Engineered Mononuclear Cells
$48,576Patrick Sean Donahue · Northwestern University · F30 · FY2016 · CA
Regulation of proliferation in vertebrate embryonic mesodermal progenitors
$48,398Cortney M Bouldin · University Of Washington · F32 · FY2011 · GM
Identification of Causal T-Cell Mechanisms in Immune Checkpoint Inhibitor Induced Myocarditis
$48,393Han Zhu · Stanford University · K08 · FY2023 · HL
The Wnt-IRF8 axis: a Novel Regulator of Myeloid-Derived Suppressor Cell Biology
$48,170Elliot David Kramer · Roswell Park Cancer Institute Corp · F30 · FY2023 · CA
Identifying and Targeting Master Regulators of Drug Resistance in Lung Adenocarcinoma through Network Analysis of Tumor Transcriptomic Data
$48,170Aaron Timothy Griffin · Columbia University Health Sciences · F30 · FY2023 · CA
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer
$48,151Timothy R Donahue · University Of California Los Angeles · R01 · FY2023 · CA
Cell Cycle Checkpoint in Response to DNA Damage
$48,106Nancy C Walworth · Univ Of Med/Dent Nj-R W Johnson Med Sch · R01 · FY2007 · GM
Defining immune footprint in tumor microenvironment following high salt synergized inflammatory cytokine mediated breast cancer progression
$48,088Anil Shanker · Meharry Medical College · U54 · FY2019 · CA
PIK3C2A is a vulnerable immunotherapeutic target in triple-negative breast cancer combination therapy
$48,068Xiyu Wang · Indiana University Indianapolis · F30 · FY2024 · CA
Membrane Ubiquitin Ligase-Driven Immune Evasion in HPV+ Head and Neck Cancer
$48,066Lexi Vu · Henry Ford Health + Michigan State University Health Sciences · F31 · FY2025 · DE
Dissecting the Gut Microbiota for Immune Checkpoint Blockade (ICB) - Resisting Microbes and Exploring the Generalizability of Microbiota-ICB Studies
$48,036Joan Shang · Icahn School Of Medicine At Mount Sinai · F30 · FY2021 · CA
Characterizing the DPP8/9 Pyroptotic Checkpoint with Chemoproteomic Protease Substrate Profiling
$48,000Andrew Griswold · Weill Medical Coll Of Cornell Univ · F30 · FY2022 · CA